Avacta GroupAVCTF 13 EBIT per Share is $-0.10 as of Dec. 2025. GuruFocus rates AVCTF with a GF Score™ of 13/100 and a GF Value™ of $0.65 (Significantly Overvalued). The stock has 9 warning signs investors should review. Among 1,178 Biotechnology companies, Avacta Group ranks worse than 53.06% on this metric.
Avacta Group's EBIT per Share for the
six
months ended in Dec. 2025 was $-0.05.
Its EBIT per Share for the trailing twelve months (TTM) ended in Dec. 2025 was $-0.10.
During the past 3 years, the average EBIT per Share Growth Rate was 12.90% per year.
During the past 5 years, the average EBIT per Share Growth Rate was 4.70% per year.
During the past 10 years, the average EBIT per Share Growth Rate was -2.50% per year.
Please click Growth Rate Calculation Example (GuruFocus) to see how GuruFocus calculates Wal-Mart Stores Inc (WMT)'s revenue growth rate. You can apply the same method to get the EBIT per Share growth rate using EBIT per Share data.
The historical rank and industry rank for Avacta Group's EBIT per Share or its related term are showing as below:
AVCTF'
s 3-Year EBIT Growth Rate Range Over the Past 10 Years
Min: -245.4 Med: 1.4 Max: 64.4
Current: 12.9
During the past 13 years, the highest 3-Year average EBIT per Share Growth Rate of Avacta Group was 64.40% per year. The lowest was -245.40% per year. And the median was 1.40% per year.
AVCTF's 3-Year EBIT Growth Rate is ranked worse than 53.06% of 1178
companies
in the Biotechnology industry
Industry Median: 15.55
vs AVCTF: 12.90
Avacta Group's EBIT for the
six
months ended in Dec. 2025 was $-21.57 Mil.
Avacta Group (OTCPK:AVCTF) EBIT per Share Explanation
EBIT is a company's earnings before interest and tax expenses are deducted. It measures a company's profit generates from operating, ignoring tax burden and capital structure. As the tax expense are not deducted, EBIT is helpful when comparing companies in the same industry but with different tax situations. Also, the interest expense are included in EBIT, making it useful to compare companies that have high interest expenses due to large amount of debt.
Avacta Group EBIT per Share Related Terms
Avacta Group EBIT per Share Historical Data
* Premium members only.
The historical data trend for Avacta Group's EBIT per Share can be seen below:
* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD. * For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.
EBIT per Share for the trailing twelve months (TTM) ended in Dec. 2025 adds up the semi-annually data reported by the company within the most recent 12 months, which was $-0.10
* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD. * For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.
Avacta Group (AVCTF) has a EBIT per Share of $-0.10 as of Dec. 2025. EBIT per Share is the amount of Earnings Before Interest and Taxes per outstanding share of the company's stock. View historical data on Avacta Group and its competitors. According to the industry distribution chart, Avacta Group ranks #625 out of 1178 companies in the Biotechnology industry, placing it in the top 53.1%.
Is Avacta Group's EBIT per Share too high?
Avacta Group's current EBIT per Share is $-0.10. Based on the distribution chart, Avacta Group ranks #625 out of 1178 companies in the Biotechnology industry, which is below the industry midpoint. Overall, Avacta Group has a GF Score™ of 13/100 and is considered Significantly Overvalued, reflecting its overall financial health beyond just this single metric.
How does Avacta Group's EBIT per Share compare to VRTX and REGN?
According to the Biotechnology industry distribution chart, Avacta Group ranks #625 out of 1178 companies for EBIT per Share. This places Avacta Group in the lower half of its industry. The industry median EBIT per Share is 15.55. See the competitive comparison table and distribution chart on this page for a detailed peer-by-peer breakdown.
What is a good EBIT per Share for a Biotechnology company?
The median EBIT per Share among Biotechnology companies is 15.55, based on 1,178 companies in the industry. Companies in the top quartile (top 25%) have a EBIT per Share significantly above this median, while those in the bottom quartile fall well below. However, EBIT per Share should not be evaluated in isolation — investors should consider it alongside profitability, growth, and financial strength metrics. Use the industry distribution chart on this page to see where any company falls relative to its peers.
What does a high EBIT per Share mean?
A high EBIT per Share can signal that a stock is expensive relative to its fundamentals. EBIT per Share is the amount of Earnings Before Interest and Taxes per outstanding share of the company's stock. View historical data on Avacta Group and its competitors. For the Biotechnology industry, the median EBIT per Share is 15.55 — values significantly above this may indicate overvaluation, while values below may suggest a bargain or underlying issues. Avacta Group's current EBIT per Share is $-0.10. However, context matters — high-growth companies often justify higher valuations. Always evaluate alongside other metrics like GF Score™ and GF Value™.
Is Avacta Group stock overvalued right now?
Based on GuruFocus' analysis, Avacta Group (AVCTF) is currently considered Significantly Overvalued. The stock's GF Value™ is $0.65, compared to a current price of $1.00 — trading 53.8% above its estimated fair value. The current EBIT per Share is $-0.10. Avacta Group's overall GF Score™ is 13/100 with 9 warning signs to review. Investors should evaluate multiple metrics — including profitability, growth, and financial strength — before making a decision.
How is EBIT per Share calculated?
EBIT per Share is calculated from a company's financial statements. For Avacta Group (AVCTF), the current EBIT per Share is $-0.10 as of Dec. 2025. GuruFocus calculates this using data sourced from SEC filings and annual reports. See the calculation section and 30-year financial data on this page for the full breakdown.
Is Avacta Group (AVCTF) Overvalued in 2026?
Based on GuruFocus' analysis, Avacta Group stock appears to be overvalued.
The current stock price of $1.00 is trading 53.8% above its estimated GF Value™ of $0.65.
GuruFocus considers Avacta Group to be Significantly Overvalued.
Key valuation signals for AVCTF:
EBIT per Share: $-0.10
GF Value™: $0.65 vs. price of $1.00 (53.8% above fair value)
No single metric tells the full story. See the AVCTF stock analysis page for a complete view including 30-year financials, guru trades, and insider activity.
Avacta Group PLC is a clinical-stage life sciences company expanding the reach of potent cancer therapies with the pre-CISION platform. pre-CISION is a proprietary warhead delivery system based on a tumor-specific protease (fibroblast activation protein or FAP) that is designed to concentrate potent warheads in the tumor microenvironment while sparing normal tissues. The company's pipeline consists of pre-CISION peptide drug conjugates (PDC) or Affimer drug conjugates (AffDC) that leverage the tumor-specific release mechanism, providing benefits over traditional antibody drug conjugates. The firm has one reportable segment, Therapeutics, which is engaged in the development of novel cancer therapies harnessing its proprietary technology. Geographically, it derives revenue from South Korea.
13GF Score
Get the complete analysis for AVCTF
EBIT per Share is just one metric. See GF Value™, 30-year financials, guru trades, warning signs, and more.
Quick Browse
Personalize
Premium Gurus 
Create New Portfolio
AVCTF has been successfully added to your 
